← Back to Screener
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Price$13.26
Favorite Metrics
Price vs S&P 500 (26W)30.77%
Price vs S&P 500 (4W)8.09%
Market Capitalization$4.23B
P/E Ratio (Annual)58.70x
All Metrics
P/CF (Annual)12.44x
Book Value / Share (Quarterly)$0.04
P/TBV (Annual)285.99x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)10.92%
Cash Flow / Share (Quarterly)$0.72
Price vs S&P 500 (YTD)6.26%
Gross Margin (TTM)36.88%
Net Profit Margin (TTM)2.39%
EPS (TTM)$0.22
10-Day Avg Trading Volume1.40M
EPS Excl Extra (TTM)$0.22
Revenue Growth (5Y)8.66%
EPS (Annual)$0.22
ROI (Annual)-3.09%
Gross Margin (Annual)36.88%
Net Profit Margin (5Y Avg)-2.13%
Cash / Share (Quarterly)$0.90
P/E Basic Excl Extra (TTM)58.70x
Revenue Growth QoQ (YoY)11.47%
EPS Growth (5Y)-18.37%
P/E Normalized (Annual)58.70x
ROA (Last FY)1.96%
Revenue Growth TTM (YoY)41.41%
EBITD / Share (TTM)$1.84
ROE (5Y Avg)-118.23%
Operating Margin (TTM)13.05%
Cash Flow / Share (Annual)$0.72
P/B Ratio213.84x
P/B Ratio (Quarterly)140.74x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.18x
Net Interest Coverage (TTM)1.60x
ROA (TTM)2.05%
EV / EBITDA (TTM)11.03x
EPS Incl Extra (Annual)$0.22
Current Ratio (Annual)2.17x
Quick Ratio (Quarterly)1.42x
3-Month Avg Trading Volume2.33M
52-Week Price Return93.73%
EV / Free Cash Flow (Annual)29.15x
P/E Incl Extra (TTM)58.70x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.05
P/S Ratio (Annual)1.40x
Asset Turnover (Annual)0.82x
52-Week High$15.42
Operating Margin (5Y Avg)6.70%
EPS Excl Extra (Annual)$0.22
CapEx CAGR (5Y)11.55%
Tangible BV CAGR (5Y)-64.27%
26-Week Price Return39.52%
Quick Ratio (Annual)1.42x
13-Week Price Return4.98%
Total Debt / Equity (Annual)136.58x
Current Ratio (Quarterly)2.17x
Enterprise Value$6,578.143
Revenue / Share Growth (5Y)-7.03%
Asset Turnover (TTM)0.86x
Book Value / Share Growth (5Y)-51.99%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.13x
Pretax Margin (Annual)4.61%
Cash / Share (Annual)$0.90
3-Month Return Std Dev34.53%
Gross Margin (5Y Avg)36.59%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)12.61%
EBITDA Interim CAGR (5Y)15.03%
ROE (Last FY)-424.61%
Net Interest Coverage (Annual)1.60x
EPS Basic Excl Extra (Annual)$0.22
P/FCF (TTM)17.88x
Receivables Turnover (TTM)3.61x
EV / Free Cash Flow (TTM)29.15x
Total Debt / Equity (Quarterly)136.58x
EPS Incl Extra (TTM)$0.22
Receivables Turnover (Annual)3.61x
ROI (TTM)-2.80%
P/S Ratio (TTM)1.40x
Pretax Margin (5Y Avg)-1.75%
Revenue / Share (Annual)$9.29
Tangible BV / Share (Annual)$0.05
Forward P/E13.44x
Free OCF CAGR (5Y)-6.32%
Price vs S&P 500 (52W)58.64%
P/E Ratio (TTM)58.70x
Year-to-Date Return10.40%
5-Day Price Return8.42%
EPS Normalized (Annual)$0.22
ROA (5Y Avg)-1.39%
Net Profit Margin (Annual)2.39%
Month-to-Date Return11.91%
Cash Flow / Share (TTM)$1.76
EBITD / Share (Annual)$1.84
Operating Margin (Annual)13.05%
LT Debt / Equity (Annual)122.72x
P/CF (TTM)12.44x
ROI (5Y Avg)-3.29%
P/E Excl Extra (TTM)58.70x
LT Debt / Equity (Quarterly)122.72x
EPS Basic Excl Extra (TTM)$0.22
P/TBV (Quarterly)285.99x
P/B Ratio (Annual)140.74x
Inventory Turnover (TTM)3.13x
Pretax Margin (TTM)4.61%
Book Value / Share (Annual)$0.04
Price vs S&P 500 (13W)2.12%
Net Margin Growth (5Y)-12.16%
Beta1.42x
P/FCF (Annual)18.75x
Revenue / Share (TTM)$9.20
ROE (TTM)-34.88%
52-Week Low$7.01
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.09
4.09
4.09
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock | 1.40x | 41.41% | 36.88% | -18.37% | $13.26 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Amneal Pharmaceuticals develops and manufactures pharmaceutical products across three segments: Affordable Medicines (generics and essential drugs), Specialty (branded pharmaceuticals for CNS and endocrine disorders), and AvKARE (government pharmaceutical distribution). Operating in the U.S., India, and Ireland, the company serves diverse market segments including cost-conscious patients, specialty therapy areas, and government agencies.